Most excitingly, however, patients with RIT1-associated NS and HCM had clinical improvement in their heart failure symptoms when treated with trametinib (Andelfinger et al., 2019), providing the strongest evidence to date that MEK inhibition may be an effective treatment strategy for patients with RASopathies. This evidence concerns the gene MAP2K7 and heart failure.